nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.10.2012 | Original article

Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer

Matched-pair analysis

verfasst von: Prof. Dr. M. Pinkawa, M.D. Piroth, R. Holy, N. Escobar-Corral, M. Caffaro, V. Djukic, J. Klotz, M.J. Eble

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Hydrogel spacer is an innovative method to protect the rectal wall during prostate cancer radiotherapy. Clinical effects are not well known.

Methods

Patients have been surveyed before, at the last day, and 2–3 months after radiotherapy using a validated questionnaire (Expanded Prostate Cancer Index Composite). Median dose to the prostate in the spacer subgroup (SP) was 78 Gy in 2 Gy fractions. The results were independently compared with two matched-pair subgroups (treated conventionally without spacer): 3D conformal 70.2 Gy in 1.8 Gy fractions (3DCRT) and intensity-modulated radiotherapy (IMRT) 76 Gy in 2 Gy fractions. There were 28 patients in each of the three groups.

Results

Baseline mean bowel bother scores were 96 points in all subgroups. Similar mean changes (SP 16, 3DCRT 14, IMRT 17 points) were observed at the end of radiotherapy. The smallest difference resulted in the spacer subgroup 2–3 months after radiotherapy (SP 2, 3DCRT 8, IMRT 6 points). Bowel bother scores were only significantly different in comparison to baseline levels in the spacer subgroup. The percentage of patients reporting moderate/big bother with specific symptoms did not increase for any item (urgency, frequency, diarrhoea, incontinence, bloody stools, pain).

Conclusion

Moderate bowel quality-of-life changes can be expected during radiotherapy irrespective of spacer application or total dose. Advantages with a spacer can be expected a few weeks after treatment.

Akimoto T, Muramatsu H, Takahashi M et al (2004) Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60:1033–1039PubMedCrossRef

Al-Mamgani A, Putten WL van, Heemsbergen WD et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72:980–988PubMedCrossRef

Bohrer M, Schröder P, Welzel G et al (2008) Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT™ (b-mode acquisition and targeting) for prostate cancer. Strahlenther Onkol 184:674–678PubMedCrossRef

Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60:1013–1015PubMedCrossRef

Dearnaley D, Syndikus I, Sumo G et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trials. Lancet Oncol 13:43–54PubMedCrossRef

Ferlay J, Parkin DM, Steliarova-Foucher E (2008) Estimates of cancer incidence and mortality in Europe 2008. Eur J Cancer 46:765–781CrossRef

Fiorino C, Sanguineti G, Cozzarini C et al (2003) Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57:953–962PubMedCrossRef

Geier M, Astner ST, Duma MN et al (2012) Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol (in press)

Goldner G, Potter R, Battermann JJ et al (2012) Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol 188:305–310PubMedCrossRef

10.

Goldner G, Sljivic S, Oismueller R et al (2011) Prostate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007. Strahlenther Onkol 187:279–283PubMedCrossRef

11.

Goldner G, Tomicek B, Becker G et al (2007) Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 67:78–83PubMedCrossRef

12.

Hatiboglu G, Pinkawa M, Vallée J et al (2012) Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int (in press)

13.

Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef

14.

ICRU (1993) ICRU report 50: prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements

15.

Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33PubMedCrossRef

16.

Michalski JM, Winter K, Purdy JA et al (2005) Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62:706–713PubMedCrossRef

17.

Moman MR, Heide UA van der, Kotte AN et al (2010) Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 96:38–42PubMedCrossRef

18.

Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed

19.

Peinemann F, Grouven U, Bartel C et al (2011) Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60:881–893PubMedCrossRef

20.

Pinkawa M, Corral NE, Caffaro M et al (2011) Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 100:436–441PubMedCrossRef

21.

Pinkawa M, Holy R, Piroth MD et al (2010) Consequential late effects after radiotherapy for prostate cancer—a prospective longitudinal quality of life study. Radiat Oncol 5:27PubMedCrossRef

22.

Pinkawa M, Holy R, Piroth MD et al (2011) Interpreting the clinical significance of quality of life score changes after radiotherapy for localized prostate cancer. Curr Urol 5:137–144CrossRef

23.

Pinkawa M, Piroth MD, Holy R et al (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479–484PubMedCrossRef

24.

Pinkawa M, Asadpour B, Gagel B et al (2006) Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys 64:856–861PubMedCrossRef

25.

Pinkawa M, Pursch-Lee M, Asadpour B et al (2008) Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther Onkol 184:679–685PubMedCrossRef

26.

Potters L, Klein EA, Kattan MW et al (2004) Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71:29–33PubMedCrossRef

27.

Prada PJ, Fernandez J, Martinez AA et al (2007) Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 69:95–102PubMedCrossRef

28.

Prada PJ, Gonzalez H, Menendez C et al (2009) Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 8:210–217PubMedCrossRef

29.

Schulze D, Liang J, Yan D et al (2009) Comparison of various online IGRT strategies: The benefits of online treatment plan re-optimization. Radiother Oncol 90:367–376PubMedCrossRef

30.

Viani GA, Stefano EJ, Alfonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74:1405–1418PubMedCrossRef

31.

Volz-Sidiropoulou E, Pinkawa M, Fischedick K et al (2008) Factor analysis of the Expanded Prostate Cancer Index Composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer. Curr Urol 2:122–129CrossRef

32.

Wei JT, Dunn RL, Litwin MS et al (2000) Development and validation of the expanded prostate cancer index composite (epic) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905PubMedCrossRef

33.

Yaparpalvi R, Hong L, Mah D et al (2009) ICRU reference dose in an era of intensity-modulated radiation therapy clinical trials: correlation with planning target volume mean dose and suitability for intensity-modulated radiation therapy dose prescription. Radiother Oncol 89:347–352CrossRef

34.

Zucca S, Carau B, Solla I et al (2011) Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol 187:473–478PubMedCrossRef

Titel: Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer
Matched-pair analysis
verfasst von: Prof. Dr. M. Pinkawa
M.D. Piroth
R. Holy
N. Escobar-Corral
M. Caffaro
V. Djukic
J. Klotz
M.J. Eble
Publikationsdatum: 01.10.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0172-6

Springer Medizin

Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer

Matched-pair analysis